<DOC>
	<DOCNO>NCT02973295</DOCNO>
	<brief_summary>This study evaluate influence Silymarin reduce laboratory , ultrasonographic ( Fibroscan ) metabolic component NAFLD . Half patient receive Silymarin ( Verum ) half receive placebo</brief_summary>
	<brief_title>Silymarin NAFLD</brief_title>
	<detailed_description>In study participate patient come regular ambulatory examination ( referred gastroenterologist , nephrologists family physicians Department Gastroenterology Department Nephrology , dialysis kidney transplantation KBC Rijeka ) one components metabolic syndrome ( hypertension , diabetes , obesity , dyslipidemia ) .Nonalcoholic fatty liver disease define transient elastography ( FibroScan , Echosens , Paris ) ; Controlled Attenuation Parameter ( CAP ) assesment liver steatosis Liver Stiffness Measurements ( LSM ) liver fibrosis . In patient cause chronic liver disease exclude ; chronic viral hepatitis , autoimmune disease metabolic liver disease well use drug cause liver steatosis fibrosis alcoholic liver disease . This study include 350 patient . Taking account possible drop-out rate around 15 % patient study period , total 400 patient randomize . Patients randomize two group . The first group consist patient NAFLD receive Verum therapy 6 month period . The second group consist patient NAFLD receive placebo 6 month period , identical Verum preparation packaging form . After 6 month therapy patient evaluate : liver enzymes metabolic laboratory parameter NAFLD ( insulin resistance , lipidogram serum glucose ) , well TE-CAP order evaluate efficiency Silymarin treatment NAFLD .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>NAFLD patient sign informed consent possibility follow instruction protocol chronic B C hepatitis usage hepatotoxic drug period 6 month inclusion chronic kidney insufficiency ( grade 4 5 ) , hemodialysis chronic liver disease opioid dependancy malignancy HIV seropositivity alcohol abuse pregnancy inability follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NAFLD ;</keyword>
	<keyword>Fibroscan</keyword>
	<keyword>Silymarin</keyword>
</DOC>